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Abstracts of the 12th ISIIH 2S49 
family had high anti-TPO and anti-TG and his aunt had 
enhanced anti-TG. The patients with HT had no clinical 
or biochemical signs of other endocrinopathies. Auto- 
antibodies typical of autoimmune polyendocrine syn- 
drome type I (anti-210H, anti-170H, anti-SCC and anti- 
GAD) were not found in repeated tests and none of the 
known Norwegian autoimmune regulator (AIRE) 
mutations were identified (i.e. in exons 6, 8 and 10) in 
family no. 1. 
Immunology: In the patients with CMC repeated 
immunological tests revealed various IgG subclass 
deficiencies and variable low T-cell and NK-cell counts. 
Slightly enhanced monocyte counts. Patients with 
CMC and HT as part of an autoimmune polyendocrine 
syndrome usually have antithyroid antibodies, and most 
patients have the autosomal recessive APECED (APS- 
1) with mutations in the AIRE gene. In a family with 
patients with CMC and HT Jennifer Puck et al.(Am J 
Hum Genet 69:791-803,200l) identified a new candidate 
linkage region on chromosome 2p. The link between a 
gene defect and the inability to clear candida remains 
unknown. An “imbalance” between Thl and Th2, with 
low Thl response and low IL-2 and IFN gamma 
secretion has been suggested, as has an impairment of 
macrophage function. Clinically our families indicate an 
autosomal dominant inheritance with variable pheno- 
type expression. They will be part of a planned, larger 
genetic linkage analysis to reveal the gene for the com- 
bination of CMC/HT. 
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Patients with impaired host defenses generally have a 
more complicated course when infected with Coccidioides 
immitis. In a consultative practice within the endemic 
area with ca. 2000 new encounters per year, we report 
20 patients with a variety of immune impairments in- 
cluding solid organ transplants, stem cell transplants, 
chemotherapy, HIV infection, steroid therapy, diabetes, 
organ failure, pregnancy and racial predisposition. 
Common observations include: (1) Need for pro- 
longed therapy. (2) High frequency of relapse. (3) Need 
for higher doses of anti-fungal agents. (4) Guarded prog- 
nosis. 
Seasonal tourism is a major industry in Tucson, 
AZ. Our experience could be helpful to international 
physicians whose immunocompromised patients might 
become ill only after returning home. 
Mechanisms of phagocytic host defense against 
Pseuakllescheria boydii (Scedosporium 
apiospermum): an emerging polyene-resistant fungal 
pathogen in immunocompromised hosts 
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Background: P. boydii (S. apzospermum) causes life- 
threatening pulmonary and disseminated infections in 
immunocompromised hosts. However, little is known 
about phagocytic host defenses against this emerging 
pathogen. 
Methods: In vitro functional phagocytic defenses of 
human polymorphonuclear leukocytes (PMNLs) 
peripheral blood monocytes (PBMs), monocyte-derived 
macrophages (MDMs), and rabbit pulmonary alveolar 
macrophages (PAMs) against two well-characterized 
clinical isolates of Pseudallescheria boydii and a control 
ATCC isolate (MYA-1163) of Aspergillus fumigatus 
were investigated. In vivo host defenses were probed in 
normal and immunocompromised rabbits by selective 
pharmacologic immunosuppression, inducing neutro- 
penia with cytosine arabinoside (AraC), suppressing 
PAMs and MDMs with methylprednisolone alone (MP), 
and suppressing PMNs, MDMs, and PAMs with the 
combination ( AraC + MP). 
Results: PMNLs were more effective in inducing hyphal 
damage than any of the other cell types examined 
(p<O.OOl). I! boydii was more sensitive to hyphal damage 
than A. fumigatus by all effector cells tested. GM-CSF 
and interferon-gamma enhanced phagocytosis of l? 
boydii conidia by MDMs (p<O.O5), suggesting their 
potential regulatory role in host response. AraC+MP 
immunosuppression permitted the greatest level of p 
boydii tissue burden (p <0.04) and hemorrhagic infarction 
(p = 0.001) in comparison to AraC or MP alone. A. fumi- 
gatus caused more pulmonary infarcts with a lower tissue 
burden in the AraC+ MP group, a higher organism burden 
in normal hosts and more frequent extrapulmonary in- 
fection. I? boydii was more resistant in vivo to ampho- 
tericin B. 
Conclusions: Phagocytic host defenses to conidia of 1? 
boydii depend upon monocytes and macrophages, while 
defense against hyphae depends upon PMNLs. P boydii 
is more susceptible to phagocytic host defenses but is 
more polyene-resistant than A. fumigatus. 
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Introduction: Systemic mycosis due to the non-Candida 
species has emerged as a serious opportunistic com- 
plication in transplant recipients. 
Methods and results: During 01, 1993, to 01, 2001, in 
48 (65.8%) patients a non-Candida fungal species was 
isolated from central venous blood culture specimen. 
Median age in 36 male and 12 female was 31, f s.d 16.6 
y. In 35, partially matched (19 had 3 human leukocyte 
antigen (HLA)-antigen mismatched) marrow graft from 
a related donor (PMRD), 5 matched, unrelated donor 
(MUD), 3 matched, sibling donor (MSD), and in 5, 
autologous transplantation was performed. All patients 
with PMRD and 4 MUD underwent T-cell depleted 
transplantation. Acute leukemia was present in 21 
(ALL 11; AML lo), chronic leukemia in 12 (CML 11; 
CLL l), lymphoma in six (NHL 4; HD 2), MDS in 4, 
multiple myeloma 2 and 12 had other conditions. And 
48.9% had profound neutropenia (ANCllOO cells/(L). 
Nine patients were receiving immunosuppressive therapy 
for acute graft-versus-host disease. The incidence of 
non-Candida fungemia in PMRD was 9.2% (35/379); 
MUD 14.7% (5/34); MSD 4.9% (3/61), and in recipients 
of autologous graft was 4.3% (5/115). In 3 individuals, 
more than one fungal species was isolated during the 
same hospitalization. Among 55 episodes, 6 Aspergillus 
spp. (1 A. fumigatus, 2 A. niger, 1 A. flavus), 3 
Dematiaceous molds (1 Alternaria, 1 Curvularia), and 2 
Trichosporon beigelii were treated as systemic fungal 
infection. Whereas, 20 Penicillium, 8 Cladosporium, 7 
Geotrichum candidum, 3 Chrysosporium, 2 Aureo- 
basidium, and one episode each of Epicoecum, Paecilo- 
myces, Sporoblomyces, and Saccharomyces cerevisiae 
were considered non-pathogenic. In 7 patients (14.6%) 
death was attributed to fungal infection. A patient with 
Aspergillus non-fumigatus spp. succumbed to hemato- 
genous dissemination 11 days after the initial episode. 
In the non-pathogen group, 3 patients with Penicillium, 
and a single patient with G. candidum, Chrysosporium, 
and Epicoecum each (16.2%) died within median 
9.5ks.d 10 days after the initial positive fungal blood 
culture. 
Conclusions: Systemic infection due to pathogenic 
non Candida species had low-attributable mortality 
(9%) in this setting. Molds with low intrinsic virulence, 
and frequent environmental contaminants may occas- 
ionally lead to fatal systemic infection in patients at 
risk. 
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We present three cases of Aspergillus endogenous endo- 
phthalmitis in immunocompromised patients. Case 1 is 
a 56 year old man with emphysema who developed 
endogenous Aspergillus endophthalmitis after brief 
treatment with corticosteroids.The eye required enuclea- 
tion. Case 2 is a 57 year old woman with bronchiolitis 
obliterans organizing pneumonia (BOOP) treated with 
corticosteroids who had Aspergillus endocarditis and 
endogenous Aspergillus endophthalmitis. She died of 
a cerebral hemorrhage. Case 3 is a 73 year old man 
with BOOP on corticosteroids who developed invasive 
pulmonary aspergillosis with dissemination to the eye. In 
an effort to define better ways to identify patients at risk 
for Aspergillus endogenous endophthalmitis and to 
determine optimal diagnostic and treatment strategies, 
we reviewed 86 cases of endogenous Aspergillus endo- 
phthalmitis reported since 1949. Predisposing medical 
conditions were present in 94%. Immunosuppression 
including organ transplantation, steroids, or malignancy 
was present in 49%, intravenous drug use was noted in 
27%, and underlying lung disease in 17%. Pars plana 
vitrectomy appears to be the highest-yield procedure for 
establishing the diagnosis. 90% of vitrectomy specimens 
yielded Aspergillus compared with 54% of vitreous 
aspirates. A. fumigatus caused infection in 51% and A. 
JEavus in 26%. Outcomes were generally poor. Only 7 of 
the 84 patients (8%) with posterior chamber involve- 
ment regained useful vision. Treatment with intravenous 
amphotericin B combined with intravitreal injection of 
amphotericin B and vitrectomy appears to be the most 
efficacious therapy. Six of 7 patients reported to have 
regained useful vision had received such treatment. 
Aspergillus endogenous endophthalmitis is difficult to 
diagnose and treat effectively. The best strategy appears 
to include diagnostic vitrectomy in high-risk individuals 
combined with intravitreal and systemic amphotericin B 
for patients in whom Aspergillus spp. are identified. 
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Background: The search for safe, effective treatment of 
invasive fungal infections has yielded novel antifungals, 
including the triazole voriconazole (Pfizer), liposomal 
preparations of amphotericin such as Abelcet (Lipo- 
some), the echinocandin micafungin (FK) (Fujisawa) 
and the pneumocandin caspofungin (MK) (Merck). 
These new antifungals are active against pathogenic 
